Introduction
============

There is mounting evidence that a history of clinical chronic prostatitis can be a risk factor for prostate cancer ([@b1-etm-0-0-3631]--[@b7-etm-0-0-3631]). As a consequence, aggressive therapy, aimed at eradicating or neutralizing the etiological agents of bacterial or abacterial forms of chronic prostatitis, is of great importance for the prompt resolution of the severe symptoms of these conditions, but may also have implications in cancer prevention.

National Institutes of Health (NIH) category II chronic bacterial prostatitis (CBP) and category III chronic prostatitis/chronic pelvic pain syndrome are the two main chronic symptomatic conditions of the prostate ([@b8-etm-0-0-3631]). While the latter is often treated with a variety of agents in an attempt to target its manifold and often uncertain etiological determinants, the former is usually managed with antibacterial agents, administered at high doses and for extended periods of time (weeks, or in some cases, months).

Fluoroquinolones such as ciprofloxacin or levofloxacin have been first-line agents for the treatment of CBP for many years, due to their broad antibacterial spectrum and efficient distribution to the prostate tissue and glandular ducts ([@b9-etm-0-0-3631]). However, fluoroquinolone-based therapy is not always feasible, due to specific contraindications (for example, a history of tendonitis or long QT syndrome) or to resistance of causative uropathogens to these agents ([@b10-etm-0-0-3631],[@b11-etm-0-0-3631]). In this regard, the resistance rates of Enterobacteriaceae and other pathogens causing community-acquired or healthcare-associated urogenital infections are increasing markedly. They exceed 50% in many parts of the world, particularly in Asia, but similar figures have been reported in other continents. For example, fluoroquinolone resistance rates in Europe and North America range from \~10% in rural areas to \>30% in established sexual networks ([@b12-etm-0-0-3631]).

Although national and international implementation of targeted stewardship may eventually decrease the deleterious impact of bacterial chemoresistance ([@b13-etm-0-0-3631]), new therapeutic options are urgently required as alternatives to fluoroquinolones. Regretfully, the armamentarium for the outpatient treatment of CBP appears to be quite limited, as most β-lactams distribute very poorly to the prostatic tissue, and trimethoprim therapy is in the majority of cases unfeasible, since worldwide resistance rates to cotrimoxazole are equivalent to or higher than those observed for fluoroquinolones, and cases of fluoroquinolone-cotrimoxazole cross-resistance are frequently reported ([@b14-etm-0-0-3631]).

Aminoglycosides are among the recommended agents for the treatment of category I acute bacterial prostatitis (ABP) ([@b15-etm-0-0-3631]). A retrospective multi-center analysis conducted in 2008 showed that an aminoglycoside is administered in 80% of cases of ABP ([@b16-etm-0-0-3631]). However, to the best of our knowledge, only case reports or small case series describing the successful administration of these agents to patients affected by CBP are available ([@b17-etm-0-0-3631]). Hence, new evidence is required to support the usage of aminoglycosides for the treatment of CBP. The present study aimed to analyze the efficacy and safety of systemic administration of aminoglycoside antibiotics to a cohort of 78 patients affected by fluoroquinolone-resistant CBP, or excluded from fluoroquinolone therapy due to various contraindications.

Patients and methods
====================

The Ethics Committee of the Principal Investigator\'s Hospital was notified of the present study, according to Italian bylaws. This was a subordinate study of a larger observational investigation, recorded in the Italian Medicines Agency AIFA clinical trial register (no. 276). For an observational retrospective study, approval is not required, and a simple notification accompanying the study protocol is sufficient (Determinazione AIFA 20/3/2008, GU 76, 31/3/2008). Patients provided written consent for processing and anonymous publication of their clinical data. This manuscript was prepared in adherence to the Strengthening the Reporting of Observational Studies in Epidemiology Statement (STROBE) guidelines for good reporting of observational studies ([@b18-etm-0-0-3631]).

### Inclusion criteria

The present study was based on the retrospective analysis of a database of \>1,700 patients with chronic prostatitis who were diagnosed and treated on an outpatient basis in Milan, Italy. Patients consecutively diagnosed with CBP from year 2001 onwards were considered.

Patients between 20 and 65 years of age were included in this study in the presence of a clinical indication for treatment with aminoglycoside antibiotics of category II CBP, diagnosed according to NIH criteria, defined in 1995 at the National Institute of Diabetes and Digestive and Kidney Diseases Chronic Prostatitis Workshop (Bethesda, MD, USA).

Patients were excluded if they presented any of the following conditions: Category I acute bacterial prostatitis, therapy with antibacterial agents or any medication effective at the prostatic level within a 90-day period prior to aminoglycoside treatment, renal/hepatic/cardiac insufficiency, elevated creatinine plasma levels, a family history or audiometric evidence of hearing impairment, indwelling catheters, cystostomy or ureterostomy, previous prostatic surgery or radiotherapy, incomplete compliance with antibacterial therapy assessed by interviewing patients at test-of-cure visits, any condition that might represent a major confounder in the evaluation of the patients with the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) for example, chronic consumption of drugs such as antidepressants or tramadol.

### Diagnostic procedures and symptom evaluation

CBP was diagnosed as previously described in detail ([@b19-etm-0-0-3631]). Briefly, the patient evaluation was based on careful collection of clinical history, a urological visit including a digitorectal examination, transrectal ultrasound, urine flowmetry \[assessment of peak urinary flow rate (Q~max~)\], and on microbiological analysis and antibiogram of lower urinary tract specimens obtained with the Meares & Stamey '4-glass' test ([@b20-etm-0-0-3631]). The total ejaculate was collected thereafter, and analyzed for pathogens and leukocytes, as previously described ([@b21-etm-0-0-3631]).

For the diagnosis of prostatic bacterial infection, colony counts in prostatic specimens (expressed prostatic secretions or post-massage urine) were required to be ≥10-fold greater than those assessed in first-voided and pre-massage midstream urine. Inflammatory leukocytes were counted in expressed prostatic secretions, post-massage urine and semen. In cases where infection by more than one pathogen was detected, microbiological tests were repeated to exclude accidental specimen contamination. Validated Italian versions of the NIH-CPSI and International Prostate Symptom Score (IPSS) tests were used to score the severity of the clinical symptoms ([@b22-etm-0-0-3631]).

The baseline workup of each candidate to aminoglycoside treatment included audiometric testing and measurement of serum creatinine.

### Study outline

After completing clinical and microbiological evaluations at the baseline visit (visit time-point 0, 'V0'), patients were treated with netilmicin (4.5 mg/kg body weight, once-daily, intramuscular), combined or not with a β-lactam antibiotic. In Italy, treatment of prostatitis is an approved indication for aminoglycosides such as netilmicin; hence, administration of these agents was on-label, non-experimental and part of routine practice. Patients remained from time-point V0 to time-point V6 on continuous treatment with the α-adrenoceptor blocker alfuzosin (10 mg/day), combined with a supplement containing a *Serenoa repens* extract (640 mg/day), lycopene (5 mg/day) and selenium (50 mg/day) in a single formulation (Profluss^®^, Konpharma, Rome, Italy) ([@b23-etm-0-0-3631]). Ketoprofen (160 mg, twice daily) was administered rectally to a group (n=11) of mildly febrile patients until normalization of the temperature was achieved.

At 4 weeks after the end of the antimicrobial treatment all patients were subjected to a complete diagnostic protocol including microbiological and clinical evaluations. This time-point was designated as visit for assessment of pathogen eradication (VERAD).

At the V6 and V12 follow-up visits (6 and 12 months after VERAD, respectively), patients were subjected to complete clinical evaluations.

### Microbiological response evaluation

The definitions of Naber *et al* were used to report the microbiological response to antibacterial therapy: i) Eradication: baseline pathogen was eradicated (\<10^3^ CFU/ml); ii) eradication with superinfection: baseline pathogen was eradicated (\<10^3^ CFU/ml) with the appearance of a new pathogen (≥10^3^ CFU ml); iii) persistence: baseline pathogen was not eradicated (≥10^3^ CFU/ml); iv) persistence with superinfection: baseline pathogen was persistent (≥10^3^ CFU/ml) with the appearance of a new pathogen (≥10^3^ CFU/ml) ([@b24-etm-0-0-3631]).

### Aminoglycoside ototoxicity risk assessment

There were 38 patients who gave written consent for genetic analysis limited to the 1555A\>G, 1494C\>T and 1556C\>T mutations in the mitochondrial DNA, which predispose an individual to irreversible sensorineural hearing loss following exposure to aminoglycosides. A specimen of cells was obtained from each patient by gently scraping the inner cheek mucosa with a sterile mucosal brush. Mitochondrial DNA was extracted, using the Quick-DNA™ Universal kit and the DNA Clean & Concentration kit (both Zymo Research Corp., Irvine, CA, USA) according to the manufacturer\'s protocol, and used as a template for the identification of ototoxicity-predisposing mutations by two different techniques: Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) ([@b25-etm-0-0-3631]) and multiplex PCR ([@b26-etm-0-0-3631]). The full sequences of the primers, the final concentration of all reagents in the reaction, and the cycling conditions were identical to those described by the developers of the two analytical techniques ([@b25-etm-0-0-3631],[@b26-etm-0-0-3631]). All personnel analyzing the genetic material and the outcome assessor were blinded to the identity of the patients. The genetic material was destroyed immediately following the release of the anonymized results of the mutation analysis. The entire procedure (handling of genetic material and data) was legitimated by the General Authorization No. 8/2014 for the Processing of Genetic Data, of the Italian Data Protection Authority.

### Data handling and statistical analysis

To analyze pre- vs. post-therapy paired differences in NIH-CPSI and IPSS scores the Wilcoxon signed-rank test was used; intergroup differences (eradicated vs. persistent cases) were analyzed with the Mann-Whitney-Wilcoxon rank sum test. The measure of central tendency for NIH-CPSI and IPSS ordinal scores was the median, and the interquartile range (IQR) was used to indicate statistical data dispersion. For continuous variables \[urinary peak flow rate, serum prostate-specific antigen (PSA) concentration and prostate volume\], paired or unpaired t-tests were used to analyze differences between means. An α error of \<5% was set as the significance level for each comparison. Comparison between paired patient proportions was made using the McNemar\'s test for correlated proportions.

The VassarStats on-line statistics platform ([vassarstats.net](vassarstats.net)) and the JASP software ([jasp-stats.org/](jasp-stats.org/)) were used for the statistical analysis of data. Post-hoc computation of achieved power was performed using the G\*Power 3.1 program ([@b27-etm-0-0-3631]).

Results
=======

### Clinical presentation of patients and treatment protocols

From the clinical database, the data of 93 patients affected by category II CBP, for whom therapy with aminoglycoside antibiotics was initially considered, were retrieved. The main reasons for aminoglycoside indication were resistance of causative pathogens to fluoroquinolones, intolerance to fluoroquinolones (for example, a history of drug-induced tendonitis or severe gastrointestinal disturbances) or ineffectiveness of previous cycles of therapy with fluoroquinolones ([Table I](#tI-etm-0-0-3631){ref-type="table"}).

Fifteen patients refused treatment or were excluded from therapy following preliminary otolaryngological tests, kidney function evaluations, or careful scrutiny of personal and family history ([Table II](#tII-etm-0-0-3631){ref-type="table"}), and 78 cases (median age, 43 years; IQR, 22 years) initiated treatment with aminoglycosides, combined or not with other antibiotics (β-lactams).

Five different antibacterial protocols were adopted. [Table III](#tIII-etm-0-0-3631){ref-type="table"} summarizes these protocols, together with the rationale for use of the listed agents. All protocols contained the aminoglycoside netilmicin (4.5 mg/kg, intramuscular), administered once-daily.

Eight patients were noncompliant with therapy or dropped-out during treatment and were excluded from the present per-protocol efficacy analysis.

There were 11 patients who presented with low-grade pyrexia (\<38.3°C/101°F), but did not show the array of signs and symptoms typical of acute bacterial prostatitis. In all cases, fever resolved within 72--96 h after the first dose of antibiotic. As prostate massage is contraindicated in febrile patients until normalization of the temperature occurs, the initial diagnosis of prostatitis was based on sonography, clinical signs and symptoms and a midstream urine culture, eventually followed by the '4-glass' test.

### Safety of aminoglycoside therapy

Therapy was in general well tolerated. Adverse effects possibly linked to aminoglycoside exposure were reported in two cases. In 1 patient the serum creatinine level increased from 1.1 mg/dl at time-point V0 to 2.3 mg/dl at time-point VERAD. This effect was reversible, and the serum creatinine level dropped to 1.2 mg/dl 8 weeks later. One patient complained of tinnitus by the end of treatment, and audiometry confirmed hearing impairment, with a notch at 8 KHz. The examining otolaryngologist suggested that therapy might have induced the worsening of a pre-existing high-frequency hearing impairment.

### Microbiological results

Eradication of the causative pathogen at time-point VERAD was observed in 55 out of 70 per-protocol patients (78.6%) and 15 patients exhibited microbiological persistence. No cases of superinfection were reported.

There were 45 and 22 patients that presented with a single-pathogen infection caused by a gram-negative or gram-positive pathogen, respectively, whereas 3 patients had mixed gram-positive/gram-negative infections ([Table IV](#tIV-etm-0-0-3631){ref-type="table"}). *Escherichia coli* and *Enterococcus faecalis* were the most prevalent pathogens (35 and 19 isolates, respectively). Single-pathogen *E.faecalis* and *E.coli* infections were eradicated in 56 and 85% of cases, respectively ([Table IV](#tIV-etm-0-0-3631){ref-type="table"}). Cases of infection recurrence were not reported in the cohort of 70 treated patients.

Microbiological eradication at time-point VERAD was observed in 10 out of 11 febrile patients (90.91%), suggesting that aminoglycoside therapy might be an effective therapeutic option in certain complicated cases. Such therapy can usually be managed in an outpatient setting.

### Clinical and laboratory findings

The clinical findings of the total patient population at enrollment (V0), at test of eradication (VERAD) and 6 or 12 months thereafter (time-points V6 and V12, respectively) are summarized in [Fig. 1](#f1-etm-0-0-3631){ref-type="fig"} and [Table V](#tV-etm-0-0-3631){ref-type="table"}.

Whereas the symptoms of prostatitis did not improve in the group of patients exhibiting pathogen persistence, the median total NIH-CPSI score, as well as the pain, voiding symptom and quality of life (QoL) subdomain scores of the NIH-CPSI decreased significantly in patients showing microbiological eradication at time-point VERAD, and showed further significant attenuation during follow-up. A caveat is that the statistical power and robustness of unpaired comparisons between groups showing microbiological eradication versus persistence are questionable, as cohorts show considerably different sizes (n=55 vs. n=15, respectively), and baseline imbalances are present (for example, baseline prostate volume).

### NIH-CPSI total score

In patients showing pathogen eradication, the NIH-CPSI total score decreased significantly from a baseline median value of 21 to 14 at time-point VERAD, and to 9 and 8 at time-points V6 and V12, respectively (P\<0.001 for all paired comparisons vs. V0, Wilcoxon signed rank test, n=55). The differences between VERAD and V6/V12, and between V12 and V6 are also significant (P\<0.001; Wilcoxon, n=55).

In patients showing persistence of infection, the score at VERAD was not significantly different from baseline values.

A clinically appreciable reduction ([@b28-etm-0-0-3631]) of ≥6 points of the total score of the NIH-CPSI questionnaire was achieved in 32 out of 55 (58%) patients in which infection was eradicated, and in 4 out of 15 (26%) patients with persistent infection (P\<0.05, two-tailed probability associated with the z-ratio, n=55).

### NIH-CPSI pain domain

In the patients in which eradication of infection was successful, the NIH-CPSI pain score decreased significantly at VERAD, declined further at time-point V6, and remained unchanged at V12 ([Fig. 1](#f1-etm-0-0-3631){ref-type="fig"}). In patients showing persistence of infection, the median pain score at VERAD was not significantly different from baseline values.

The disease severity was categorized using the full pain domain score of the NIH-CPSI, according to Wagenlehner\'s criteria ([@b29-etm-0-0-3631]). At time-point V0, 27 patients in the eradicated group showed mild pain (0--7 points), 22 patients moderate pain (8--13 points) and 6 severe pain (14--21 points). At the end of therapy 49, 6 and 0 patients showed mild, moderate and severe pain, respectively \[P\<0.01, two-tailed McNemar\'s test for correlated proportions, dichotomized data (mild vs. moderate/severe), n=55\].

### Voiding signs and symptoms

Voiding symptom scores decreased significantly at VERAD in the eradicated group, and were sustained at time-points V6 and V12 ([Fig. 1](#f1-etm-0-0-3631){ref-type="fig"}). This finding was also evident when the results of the IPSS test were analyzed ([Table V](#tV-etm-0-0-3631){ref-type="table"}). In patients showing persistence of infection, the voiding symptom scores at VERAD were not significantly different from baseline values.

The reduction of voiding symptoms was confirmed by assessment of the peak urinary flow and of the bladder voiding efficiency: Mean Qmax increased from 17.93 ml/sec at V0 to 18.97 ml/sec at VERAD, and the percentage bladder voided volume (%BVV; 89% of total bladder content at V0) was also significantly increased at VERAD (98%) (P\<0.05 for both comparisons, paired, two-tailed t-test, n=55; [Table V](#tV-etm-0-0-3631){ref-type="table"}); these two signs remained sustainedly improved throughout the entire follow-up period.

In patients showing pathogen persistence, a significant increase of the peak urinary flow (from 18.2 ml/sec at V0 to 19.9 ml/sec at VERAD) was observed. In this cohort, as well as in the larger cohort of patients in which infection was eradicated, the administration of alfuzosin up to time-point V6 may have acted as a major confounder, and no conclusion can be drawn from data concerning short-term improvement of voiding symptoms. However, [Fig. 1](#f1-etm-0-0-3631){ref-type="fig"} shows that the improvement of voiding symptoms was sustained at the 1-year follow-up time-point (V12), when patients had been off alfuzosin therapy for 6 months.

### NIH-CPSI QoL domain

Pain and voiding symptom relief, assessed with the NIH-CPSI test, resulted in significant and sustained attenuation of the impact of the disease on QoL in patients with eradiation of infection, but not in patients showing persistent infection ([Fig. 1](#f1-etm-0-0-3631){ref-type="fig"}).

### Sonography and laboratory assessments

A significant reduction of the prostatic volume was identified in patients showing pathogen eradication at time-point VERAD (mean difference, 5.4 ml lower; P\<0.0001, paired t-test, n=55), but not in patients not responding to the antibacterial therapy (25.27 ml at VERAD vs. 25.5 ml at V0; P≥0.05, n=15).

The mean PSA serum level decreased significantly in the eradicated group (mean difference, 0.23 ng/ml lower; P\<0.0001, n=55). However, PSA also decreased significantly in patients showing pathogen persistence (2.29 at VERAD vs. 3.31 at V0; P\<0.05, n=15).

### Study power

Post-hoc computation of achieved power of the analyses was based on an α error probability of 0.05, a calculated correlation between paired datasets equal to 0.7 and a sample size of 55 patients with eradicated infection. The estimated power for the pre- and post-therapy paired comparison of the total score of the NIH-CPSI test was \>0.9. Sensitivity analysis, given a sample size of 55, a normal distribution (two-tailed), an α error probability of 0.05, and an imputed power of 0.99, resulted in a required effect size of 1.007 (the effect size for the above comparison calculated in the present study was 1.2).

Discussion
----------

Few drugs are able to reach the prostatic ducts or acini via the systemic circulation, due to the existence of a blood-prostate barrier activity preventing the distribution of a number of chemicals, including antibacterial agents, to the various cells and regions within the gland ([@b30-etm-0-0-3631]).

Goto *et al* authored one of the few studies investigating the distribution of aminoglycosides and other four different antibacterials to prostatic fluid/secretions ([@b31-etm-0-0-3631]). It was shown that the aminoglycoside amikacin (200 mg, intramuscular) reached the highest concentrations in prostatic fluids (3.2 µg/ml), compared with β-lactams (piperacillin, 0.3 µg/ml), tetracyclines (minocycline, 0.62 µg/ml) or fluoroquinolones (ofloxacin, 1.3 µg/ml), although the latter showed the highest prostatic fluid-to-serum ratio (ofloxacin: 0.9; amikacin: 0.25) ([@b31-etm-0-0-3631]). Notably, patients enrolled in the study by Goto et al were not affected by acute prostatitis, known to facilitate the distribution of any drug to the prostate ([@b31-etm-0-0-3631]). Thus, positive evidence is available about the distribution of certain aminoglycosides to the sites of chronic infection in the prostate.

Cure of CBP achieved with aminoglycosides was reported as early as 1976 and 1991 by Pfau and Sacks in isolated cases or a small series of patients treated with parenteral kanamycin (1 g twice daily for 3 days, and 500 mg twice daily for 11 days; n=13) or streptomicin (1 g/day for 12 days; 1 case) ([@b32-etm-0-0-3631],[@b33-etm-0-0-3631]), but to the best of our knowledge the overall evidence in this respect is scant.

Within the limits of an observational study, the data in the present study show that microbiological eradication and sustained clinical symptom remission was achieved in 79% of patients (or 71%, if a intent-to-treat setting is considered, including 8 noncompliant/dropped-out patients) subjected to a course of treatment with an aminoglycoside, administered alone or in combination with a β-lactam antibiotic. Notably, similar pathogen eradication rates, ranging between 70 and 80%, have been reported in the past in CBP patients treated with various fluoroquinolones ([@b19-etm-0-0-3631],[@b24-etm-0-0-3631],[@b34-etm-0-0-3631],[@b35-etm-0-0-3631]). In summary, the results of the present study suggest that aminoglycosides may be administered to selected CBP patients, provided that candidates to therapy are at low risk for the serious adverse effects of these agents.

Therapy with aminoglycosides exposes patients to the risk of hearing impairment. In particular, the carriers of the 1555 A\>G point-mutation within the mitochondrial DNA locus of the 12S ribosomal RNA develop profound and irreversible non-syndromic sensorineural hearing loss even after short-term exposure to aminoglycosides ([@b36-etm-0-0-3631]). One in 520 (0.19%) European children, 6 in 865 Chinese newborns (0.7%), and 1 in 500 adults of European descent (0.2%) are estimated to be carriers of this mutation, and are at risk for such severe toxic effects ([@b37-etm-0-0-3631]--[@b39-etm-0-0-3631]). Other important ototoxicity-predisposing mutations have been discovered, for example the 1494 C\>T and 1556 C\>T substitutions in the same 12S rRNA ([@b40-etm-0-0-3631],[@b41-etm-0-0-3631]). In our routine clinical practice, consenting patient candidates for aminoglycoside therapy are screened for a small panel of mutations predisposing to severe, irreversible hearing loss. This preliminary analysis can be performed in few hours prior to the first dose of the antibiotic, and allows safer administration of aminoglycosides. However, a negative pharmacogenetic examination result does not exempt patients from less severe forms of hearing impairment, possibly caused by reactive oxygen species. Administration of aspirin has been shown to partly protect patients from these forms of ototoxicity ([@b42-etm-0-0-3631]).

In conclusion, administration of aminoglycosides eradicated causative pathogens in 79% of patients and significantly decreased the symptoms of the disease, as assessed with the NIH-CPSI and IPSS questionnaires. The impact of CBP on the QoL of patients was also significantly attenuated. Therapy was also effective in significantly decreasing the prostate volume, probably by acting on inflammatory edema. The therapy was in general well tolerated, and genetic testing for mitochondrial mutations predisposing to sensorineural deafness allowed safer administration of the antibiotic in a considerable fraction of patients. Thus, the data presented in this paper indicate that aminoglycosides may be an interesting option for the treatment of CBP in specific, carefully selected cases. These findings should be confirmed and further validated in a randomized-controlled setting.

![NIH-CPSI scores, assessed at baseline (time-point V0), at test of microbiological eradication (VERAD), and at follow-up (V6 or V12, 6 or 12 months after VERAD, respectively). Results are stratified according to the microbiological outcome of therapy (eradication vs. persistence of infection). Median values of NIH-CPSI scores are indicated, and interquartile range bars are shown. (A) Pain domain, (B) voiding symptoms domain, (C) impact of the disease on patients\' QoL and (D) total NIH-CPSI scores. Due to the retrospective nature of the study, the follow-up data of patients showing microbiological persistence are missing, as these patients were routed towards a third-level diagnostic and therapeutic protocol. \*P\<0.001 vs. V0, paired comparison (Wilcoxon signed rank test). \*\*P\<0.001 vs. VERAD, paired comparison (Wilcoxon signed rank test). \*\*\*P\<0.05 vs. V6, paired comparison (Wilcoxon signed rank test). ^\#^P≥0.05 vs. V0, paired comparison (Wilcoxon signed rank test). ^§^P\<0.01, intergroup comparison at VERAD (eradication vs. infection persistence groups), Mann-Whitney-Wilcoxon rank sum test. ^§§^P≥0.05, intergroup comparison at VERAD (eradication vs. infection persistence groups), Mann-Whitney-Wilcoxon rank sum test. NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom Index; VERAD, visit for assessment of pathogen eradication; QoL, quality of life.](etm-12-04-2585-g00){#f1-etm-0-0-3631}

###### 

Rationale for aminoglycoside therapy.

        Adverse effects to first-line agents               
  ----- -------------------------------------- ----- ----- -----
  Yes                                                        3
        Yes                                                11
                                               Yes           7
                                                     Yes   15
  Yes                                          Yes           2
        Yes                                          Yes     5
                                               Yes   Yes     6
  Yes   Yes                                    Yes           6
        Yes                                    Yes         14
        Yes                                    Yes   Yes     9

Rationale for aminoglycoside therapy in the patient population (n=70) was based on the following single or combined factors: Persistent infection after full-dose first-line oral therapy (750 mg/day levofloxacin or 1 g/day ciprofloxacin for 4--6 weeks) directed against fluoroquinolone-susceptible pathogens; a history of moderate or severe adverse effects to fluoroquinolones; and resistance of causative pathogens to fluoroquinolones.

###### 

Rationale for rejection or contraindication of treatment following initial general indication of aminoglycoside therapy.

  Rationale                                                                                    Patients, n
  -------------------------------------------------------------------------------------------- -------------
  Professional musician                                                                          1
  Semiprofessional involvment in music or professional activity requiring fine hearing           5
  Referred history of reversible hearing impairment upon treatment with aminoglycosides          2
  High frequency (4,000 Hz) hearing impairment assessed during audiometry performed            
  prior to aminoglycoside therapy initiation                                                     2
  Bilateral hearing impairment in family with matrilinear hearing loss                           2
  Elevated serum creatinine assessed during previous exposure to amikacin                        1
  Unilateral hearing impairment referred during anamnestic interview prior to aminoglycoside   
  therapy initiation                                                                             2
  Referred tinnitus plus recurrent otitis                                                        1
  Total                                                                                        15

###### 

Antibacterial protocols administered to CBP patients and rationale for drug selection.

  Therapeutic protocol   Drugs and dosages                                                                                                                                 Rationale
  ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1                      Netilmicin, intramuscular, 4.5 mg/kg, once daily for 2 weeks. Cefuroxime axetil, oral, 250 mg, twice daily for 2 weeks                            Cefuroxime was administered to exploit the synergic activity of combined aminoglycosides and β-lactams; this 2nd generation cephalosporin showssufficient prostate penetration ([@b43-etm-0-0-3631]). Pathogen sensitivity was assessed by antibiogram
  2                      Netilmicin, intramuscular, 4.5 mg/kg, once daily for 2 weeks. Cefoperazone, intramuscular, 1 g, twice daily for 2 weeks                           Cefoperazone was administered to exploit the synergic activity of combined aminoglycosides and β-lactams; this 3rd generation cephalosporin shows sufficient prostate penetration ([@b43-etm-0-0-3631]). Pathogen sensitivity was assessed by antibiogram
  3                      Netilmicin, intramuscular, 4.5 mg/kg, once daily for 2 weeks. Piperacillin, 2 g, plus tazobactam, 250 mg, intramuscular, once daily for 2 weeks   Piperacillin was administered to exploit the synergic activity of combined aminoglycosides and β-lactams in the presence of resistance to cephalosporins (pathogen sensitivity assessed by antibiogram), or upon cephalosporin contra-indication. Piperacillin shows adequate prostate penetration ([@b44-etm-0-0-3631])
  4                      Netilmicin, intramuscular, 4.5 mg/kg, once daily for 2 weeks. Co-amoxiclav 875 mg + 125 mg, oral, twice daily for 2 weeks                         Co-amoxiclav can be recovered in the prostate tissue ([@b44-etm-0-0-3631]), and was administered to exploit the synergic activity of combined aminoglycosides and β-lactams in the presence of resistance to cephalosporins (pathogen sensitivity assessed by antibiogram), or of contraindication to cephalosporins or piperacillin
  5                      Netilmicin, intramuscular, 4.5 mg/kg, once daily for 2 weeks                                                                                      Netilmicin was administered as single agent when causative pathogens showed resistance to β-lactams.

CBP, chronic bacterial prostatitis.

###### 

Microbiological eradication of each pathogen, assessed at time-point VERAD in the per-protocol study cohort of a total of 70 patients.

  Pathogen                             Eradicated, n (%)   Persistent, n (%)   Total cases
  ------------------------------------ ------------------- ------------------- -------------
  *Escherichia coli*                   29 (85.29)          5 (14.71)           34
  *Enterococcus faecalis*                9 (56.25)         7 (43.75)           16
  *Staphylococcus aureus*              2 (100.00)          --                    2
  *Proteus mirabilis*                  2 (100.00)          --                    2
  *Klebsiella oxytoca*                 2 (66.67)           1 (33.33)             3
  *Pseudomonas aeruginosa*             1 (100.00)          --                    1
  *Enterobacter cloacae*               --                  1 (100.00)            1
  *Morganella morganii*                1 (50.00)           1 (50.00)             2
  *Haemophylus* spp.                   1 (100.00)          --                    1
  *Citrobacter* spp.                   1 (100.00)          --                    1
  *Streptococcusβ-haemolyticus*        4 (100.00)          --                    4
  *E. faecalis* plus *E. coli*         1 (100.00)          --                    1
  *E. faecalis* plus *P. aeruginosa*   2 (100.00)          --                    2
  Total                                55 (78.57)          15 (21.43)          70

VERAD, visit for assessment of pathogen eradication.

###### 

Serum PSA, prostate volume, Qmax, % voided bladder and IPSS at various time points.

                         Study time point                                                                                                                                                                                                  
  ---------------------- ---------------------------- ------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------------------
  PSA (ng/ml)                                                                                                                                                                                                                              
    Eradicated           3.32±2.89                    1.89±1.37^[a](#tfn5-etm-0-0-3631){ref-type="table-fn"}^                                                                   NA                                                         NA
    Persistent           3.31±3.73                    2.29±1.98^[b](#tfn6-etm-0-0-3631){ref-type="table-fn"},\ [c](#tfn7-etm-0-0-3631){ref-type="table-fn"}^                    NA                                                         NA
  Prostate volume (ml)                                                                                                                                                                                                                     
    Eradicated           30.0±15.44                   24.6±12.17^[a](#tfn5-etm-0-0-3631){ref-type="table-fn"}^                                                                  NA                                                         NA
    Persistent           25.5±9.21                    25.27±14.50^[c](#tfn7-etm-0-0-3631){ref-type="table-fn"},\ [d](#tfn8-etm-0-0-3631){ref-type="table-fn"}^                  NA                                                         NA
  Qmax (ml/sec)                                                                                                                                                                                                                            
    Eradicated           17.93±7.25                   18.97±5.62^[b](#tfn6-etm-0-0-3631){ref-type="table-fn"}^                                                                  19.32±5.48^[b](#tfn6-etm-0-0-3631){ref-type="table-fn"}^   18.66±4.06^[b](#tfn6-etm-0-0-3631){ref-type="table-fn"}^
    Persistent           18.21±5.60                   19.93±5.73^[b](#tfn6-etm-0-0-3631){ref-type="table-fn"},\ [c](#tfn7-etm-0-0-3631){ref-type="table-fn"}^                   NA                                                         NA
  \% voided bladder                                                                                                                                                                                                                        
    Eradicated           88.95±17.25                  97.75±9.18^[b](#tfn6-etm-0-0-3631){ref-type="table-fn"}^                                                                  97.90±8.00^[b](#tfn6-etm-0-0-3631){ref-type="table-fn"}^   96.75±12.04^[b](#tfn6-etm-0-0-3631){ref-type="table-fn"}^
    Persistent           93.85±11.37                  97.66±9.03^[c](#tfn7-etm-0-0-3631){ref-type="table-fn"},\ [d](#tfn8-etm-0-0-3631){ref-type="table-fn"}^                   NA                                                         NA
  IPSS score                                                                                                                                                                                                                               
    Eradicated             12 ([@b9-etm-0-0-3631])    8.5 (5.5)^[e](#tfn9-etm-0-0-3631){ref-type="table-fn"}^                                                                   7 (4.25)^[e](#tfn9-etm-0-0-3631){ref-type="table-fn"}^     7 ([@b5-etm-0-0-3631])^[e](#tfn9-etm-0-0-3631){ref-type="table-fn"}^
    Persistent           10.25 ([@b3-etm-0-0-3631])     9 ([@b3-etm-0-0-3631])^[f](#tfn10-etm-0-0-3631){ref-type="table-fn"},\ [g](#tfn11-etm-0-0-3631){ref-type="table-fn"}^   NA                                                         NA

Results were measured at baseline (V0), at test of microbiological eradication (VERAD), and at 6 or 12 months follow-up (V6 and V12, respectively). Results are stratified according to the microbiological outcome of therapy (eradicated vs persistent infection). Median values and interquartile ranges (in parentheses) of the IPSS, and mean ± standard deviations of all other endpoints are presented. Due to the retrospective nature of the study, some follow-up data are missing, as patients showing microbiological persistence were managed with a different, third-level diagnostic and therapeutic protocol.

P\<0.0001 vs. V0, paired t-test

P\<0.05 vs. V0, paired t-test

P≥0.05, intergroup comparison (unpaired t-test)

P≥0.05 vs. V0, paired t-test

P\<0.05 vs. V0, paired comparison (Wilcoxon signed rank test)

P≥0.05 vs. V0, paired comparison (Wilcoxon signed rank test)

P≥0.05, intergroup comparison (Mann-Whitney-Wilcoxon rank sum test). VERAD, visit for assessment of pathogen eradication; IPSS, International Prostate Symptom Score; Qmax, urinary peak flow rate; PSA, serum prostate-specific antigen; NA, not assessed.

[^1]: Contributed equally
